MAYO LICENSE AGREEMENT (Details) (USD $)	1 Months Ended			1 Months Ended			3 Months Ended			12 Months Ended	1 Months Ended					1 Months Ended	3 Months Ended
	May 31, 2013 item	Mar. 31, 2013	Dec. 31, 2009	May 31, 2012 License Agreement MAYO	Jun. 30, 2011 License Agreement MAYO	Jun. 30, 2009 License Agreement MAYO item	Mar. 31, 2013 License Agreement MAYO	Mar. 31, 2012 License Agreement MAYO	Sep. 30, 2009 License Agreement MAYO	Dec. 31, 2012 License Agreement MAYO	Sep. 30, 2011 License Agreement MAYO Warrant covering 1,000,000 shares of common stock	Jun. 30, 2011 License Agreement MAYO Warrant covering 1,000,000 shares of common stock	Sep. 30, 2010 License Agreement MAYO Warrant covering 1,000,000 shares of common stock	Mar. 31, 2010 License Agreement MAYO Warrant covering 1,000,000 shares of common stock	Jun. 11, 2009 License Agreement MAYO Warrant covering 1,000,000 shares of common stock	Jan. 31, 2013 License Agreement MAYO Warrant covering 250,000 shares of common stock	Mar. 31, 2013 License Agreement MAYO Warrant covering 250,000 shares of common stock	Jun. 11, 2009 License Agreement MAYO Warrant covering 250,000 shares of common stock
Warrants
Number of common stock purchase warrants granted						2
Exercise price (in dollars per share)		$ 0.01													$ 1.90			$ 1.90
Number of shares of common stock covered by warrants			75,000												1,000,000			250,000
Vesting period of warrant (in years)																	4 years
Warrants exercised, gross (in shares)											250,000	250,000	300,000	200,000		85,000
Warrants forfeited (in shares)											56,641	60,246	97,853	86,596		14,008
Warrants exercised, net of forfeiture (in shares)											193,359	189,754	202,147	113,404		70,992	165,000
Royalty Payments
Minimum royalty payments							$ 25,000			$ 10,000
Other Payments
Upfront payment									80,000
Milestone payment on the commencement of patient enrollment in a human cancer screening clinical							250,000
Milestone payment contingent upon FDA approval					250,000		500,000
Payments for research and development efforts							100,000	200,000
Estimated liability for research and development efforts							400,000	100,000
Amendments - May 2012
Number of shares of restricted stock granted as a consideration for the expanded license				97,466
Vesting right percentage of restricted stock	25.00%
Number of equal annual installments in which restricted stock are to be vested	3
Licensing expense recognized in connection with the restricted stock grant										$ 1,000,000